Immunomodulatory Strategies for Huntington's Disease Treatment
- PMID: 28606048
- DOI: 10.2174/1871527316666170613084801
Immunomodulatory Strategies for Huntington's Disease Treatment
Abstract
Background & objective: Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disease characterized by selective loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding the protein huntingtin. Despite the fact that the HD gene was identified over 20 years ago, there is no effective disease-modifying therapy for HD and only symptomatic therapies are available to date. Recently, new agents and procedures have been investigated for HD and many of them have focused on immunomodulatory and/or anti- inflammatory strategies.
Conclusion: The objective of the current review is to summarize data on the therapeutic strategies to treat HD that are based on immunomodulatory effects.
Keywords: Huntington's disease; disease modifying treatment; inflammation; stem cells; symptomatic therapies; treatment.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Huntington's disease: clinical presentation and treatment.Int Rev Neurobiol. 2011;98:297-323. doi: 10.1016/B978-0-12-381328-2.00013-4. Int Rev Neurobiol. 2011. PMID: 21907093 Review.
-
Promises and pitfalls of immune-based strategies for Huntington's disease.Neural Regen Res. 2017 Sep;12(9):1422-1425. doi: 10.4103/1673-5374.215245. Neural Regen Res. 2017. PMID: 29089980 Free PMC article. Review.
-
Clinical and genetic characteristics in patients with Huntington's disease from China.Neurol Res. 2016 Oct;38(10):916-20. doi: 10.1080/01616412.2016.1214555. Epub 2016 Jul 29. Neurol Res. 2016. PMID: 27483361
-
Clinical Features of Huntington's Disease.Adv Exp Med Biol. 2018;1049:1-28. doi: 10.1007/978-3-319-71779-1_1. Adv Exp Med Biol. 2018. PMID: 29427096 Review.
-
Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.J Int Neuropsychol Soc. 2017 Feb;23(2):159-170. doi: 10.1017/S1355617716001132. J Int Neuropsychol Soc. 2017. PMID: 28205498 Free PMC article.
Cited by
-
Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31.Neurotherapeutics. 2021 Apr;18(2):1039-1063. doi: 10.1007/s13311-021-01023-8. Epub 2021 Mar 30. Neurotherapeutics. 2021. PMID: 33786806 Free PMC article.
-
Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.J Cell Mol Med. 2019 Feb;23(2):1581-1592. doi: 10.1111/jcmm.14113. Epub 2018 Dec 25. J Cell Mol Med. 2019. PMID: 30585395 Free PMC article.
-
Neuroinflammation in Huntington's disease: Causes, consequences, and treatment strategies.J Huntingtons Dis. 2025 Aug;14(3):258-269. doi: 10.1177/18796397251338207. Epub 2025 Aug 7. J Huntingtons Dis. 2025. PMID: 40772423 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical